Lawrence B. Holzman

Dr. Lawrence B. Holzman serves as Professor of Medicine and Director of the Glomerular Disease Center within the Renal-Electrolyte and Hypertension Division at the Perelman School of Medicine, University of Pennsylvania. His NIH-funded research program bridges molecular biology and clinical nephrology with international recognition in podocyte signaling mechanisms.

His educational foundation includes:

• B.A. in Biophysics from University of Pennsylvania (1980)
• M.D. from UMDNJ - New Jersey Medical School (1984)

Dr. Holzman's research revolutionized understanding of glomerular filtration through seminal discoveries in podocyte biology. His laboratory first demonstrated nephrin's localization to the slit diaphragm and established FAT1's critical role in actin cytoskeletal dynamics. Simultaneously, his team discovered and cloned DLK (Dual Leucine Zipper Kinase), revealing its function as a MAP3K regulating JNK activation and insulin sensitivity pathways that influence obesity development. These dual research trajectories converge on molecular mechanisms underlying proteinuria and glomerular disease progression.

Analysis of his publication record shows consistent focus on podocyte-specific signaling pathways (68% of recent work), with emerging emphasis on translational biomarker discovery (22%) and multicenter clinical cohort development (10%). Key methodological contributions include transgenic mouse models for podocyte-specific protein manipulation now adopted globally in nephrology research.

Dr. Holzman leads major NIH-funded initiatives including CureGN and NEPTUNE multicenter studies, directing collaborative efforts across 27 clinical sites to establish standardized protocols for glomerular disease classification and treatment. His laboratory maintains active partnerships with the Lupus Nephritis Clinic and Renal Pathology Department for integrated basic-clinical research.

The Holzman Lab operates within the Renal-Electrolyte and Hypertension Division's state-of-the-art facilities, utilizing advanced imaging, transgenic platforms, and clinical data integration systems. Current projects focus on DLK-mediated metabolic pathways in diabetic kidney disease and FAT1-dependent repair mechanisms following podocyte injury, with several therapeutic targets in preclinical validation.